Johnson & Johnson Loses Remicade Patent in Appeal Ruling

(Bloomberg) -- Johnson & Johnson’s patent on its top-selling arthritis drug Remicade is invalid, a U.S. appeals court ruled Tuesday in a defeat to the drugmaker that just last week lost a patent on...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.